Mesoblast reports $115M Ryoncil revenue in first year post-FDA approval, expands trials for serious inflammatory diseases.
Mesoblast announced $36 million in net revenue for Q4 and $115 million for the first full year following FDA approval of its Ryoncil therapy, used to treat steroid-refractory acute graft versus host disease (SR-aGvHD) in children. The company is expa...
